Navigation Links
Simple drug has the potential to save many lives threatened by malaria

A simple drug, given to children with severe malaria before they reach hospital, has the potential to save many lives, say researchers in this week's BMJ.

Every year over a million children die of malaria in Africa. The majority of fatalities occur outside hospital, especially in rural areas. For those who do make it to hospital, half of deaths occur within 24 hours of admission.

Conventional treatment, given by injection, is not possible to administer outside hospital, so buying time by starting treatment which is easy to administer in the community is crucial.

Researchers in Uganda compared the effectiveness and safety of conventional treatment (intravenous quinine) with an alternative treatment (artemether, given as a suppository) in 103 children aged between 6 months and 5 years with severe malaria.

They found the two treatments broadly comparable and suggest that rectal artemether could be used to treat severe malaria where qualified staff and equipment for intravenous therapy is not available.

These are encouraging results, say experts in an accompanying editorial. Although a single trial of this size cannot alone be the basis for policy change, rectal artemisinins might be one safe and effective way to reduce the risk of children dying before reaching hospital.

Providing effective antimalarial treatment close to home to reduce delay has the potential to save many lives, they conclude.

You can read the paper here.


'"/>

Source:News-Medical Net


Page: 1

Related biology news :

1. Discovery Promises Simpler Therapy for Sickle Cell Disease
2. Simple sea sponge helps scientists understand tissue rejection
3. Simple explanation for complex pattern of feather development
4. Simple idea to dramatically improve dengue vaccinations
5. Simple home spit test to spot deadly pre-eclampsia
6. MetaChip provides quick, efficient toxicity screening of potential drugs
7. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
8. Engineers improve plastics potential for use in implants by linking it to biological material
9. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
10. Improving the potential of cancer vaccines
11. Snapin: A protein with therapy potential for autism
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: